Roche's Tecentriq combo wins fast FDA review in race to catch rivals
ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday.
from Reuters: Health News https://reut.rs/2HWFeME
http://bit.ly/2zwRqiM